Advertisement

Systematic Review Findings on Prostate Cancer Survivorship

  • Sanchia S. Goonewardene
  • Raj Persad
Chapter

Abstract

As demonstrated by these results, there is a large area of need, largely unmet [1]. Survivorship care programmes are in general, lacking. Psychosexual care and medical care, quality of life [2] and patient self-efficacy [3] are the main areas of development in a structured survivorship pathway. Without this, increased primary health care use results [4]. Communication and discussion of physical symptoms are central to a survivorship pathway [5, 6]. Healthcare input is an important factor associated with successful survivorship care, covering side effects and therapy and medical health.

References

  1. 1.
    McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bhindi B, Mamdani M, Kulkarni GS, Finelli A, Hamiton RJ, Trachtenberg J, Zlotta AR, Toi A, Evans A, Van Der Kwast TH, Fleshner NE. Prostate biopsy trends in relation to U.S. Preventative Task for recommendations against routine PSA-based screening: a time-series analysis. Eur Urol Suppl. 2014;13(1):e852.CrossRefGoogle Scholar
  3. 3.
    Meade CD, Calvo A, Rivera MA, Baer RD. Focus groups in the design of prostate cancer screening information for Hispanic farmworkers and African American men. Oncol Nurs Forum. 2003;30:967–75.CrossRefGoogle Scholar
  4. 4.
    Megas G, Papadopoulos G, Stathouros G, Moschonas D, Gkialas I, Ntoumas K. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor Tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. BJU Int. 2013;112:E169–76.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin WP, Wei JT. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23:2772–80.CrossRefGoogle Scholar
  6. 6.
    Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Sanda MG. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006;68:166–71.CrossRefGoogle Scholar
  7. 7.
    Miner MM. Erectile dysfunction: a harbinger for cardiovascular events and other comorbidities, thereby allowing a ‘window of curability’. Int J Clin Pract. 2009;63:1123–6.CrossRefGoogle Scholar
  8. 8.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Online). 2009;339:332–6.Google Scholar
  9. 9.
    Molton IR, Siegel SD, Penedo FJ, Dahn JR, Kinsinger D, Traeger LN, Carver CS, Shen BJ, Kumar M, Schneiderman N, Antoni MH. Promoting recovery of sexual functioning after radical prostatectomy with group-based stress management: the role of interpersonal sensitivity. J Psychosom Res. 2008;64:527–36.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mosher CE, Sloane R, Morey MC, Snyder DC, Cohen HJ, Miller PE, Demark-Wahnefried W. Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. Cancer. 2009;115:4001–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
  • Raj Persad
    • 2
  1. 1.The Royal Free Hospital and UCLLondonUnited Kingdom
  2. 2.North Bristol NHS TrustBristolUnited Kingdom

Personalised recommendations